A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
Launched by ELI LILLY AND COMPANY · Apr 21, 2025
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
The ATTAIN-Hypertension trial is a research study looking at a new medication called orforglipron (LY3502970) to see how well it works in treating high blood pressure (hypertension) in people who are overweight or have obesity. This study is part of a larger group of studies and aims to find out both the effectiveness and safety of this treatment.
The trial is not yet recruiting participants, but it will include adults aged 65 to 74 years, regardless of gender. To participate, individuals will need to meet specific health criteria, which are detailed in a separate master protocol. Participants can expect to be closely monitored during the study to assess how the medication affects their blood pressure and overall health. If you or someone you know fits the age group and is dealing with hypertension and excess weight, this study might provide an opportunity to explore a new treatment option.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • refer to the GZPL master protocol for screening eligibility.
- Exclusion Criteria:
- • refer to the GZPL master protocol for screening eligibility.
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Ogden, Utah, United States
Buenos Aires, , Argentina
Richmond, Virginia, United States
Honolulu, Hawaii, United States
Newport News, Virginia, United States
Berlin, , Germany
Waterbury, Connecticut, United States
Ioannina, , Greece
Thessaloniki, , Greece
Phoenix, Arizona, United States
Wuxi, Jiangsu, China
Chengdu, Sichuan, China
Barcelona, , Spain
Northridge, California, United States
Sevilla, Andalucía, Spain
Athens, , Greece
Bydgoszcz, Kujawsko Pomorskie, Poland
Thessaloniki, , Greece
Chuo Ku, Tokyo, Japan
Siping, Jilin, China
Saint Peters, Missouri, United States
Columbus, Ohio, United States
Lishui, Zhejiang, China
Jinan, Shandong, China
Hodonin, , Czechia
Boca Raton, Florida, United States
Mckinney, Texas, United States
Covina, California, United States
Chuo Ku, Tokyo, Japan
Sevilla, , Spain
Saratoga Springs, New York, United States
Bhubaneswar, Odisha, India
Oldenburg, Schleswig Holstein, Germany
Piotrkow Trybunalski, , Poland
New Delhi, Delhi, India
Sevilla, , Spain
Las Vegas, Nevada, United States
Troy, Michigan, United States
Essen, Nordrhein Westfalen, Germany
Leipzig, Sachsen, Germany
Athens, Attikí, Greece
Wroclaw, Dolnośląskie, Poland
Wroclaw, , Poland
Buenos Aires, , Argentina
Luoyang Shi, Henan, China
Bangalore, Karnataka, India
Yamato Shi, Kanagawa, Japan
Las Vegas, Nevada, United States
North Richland Hills, Texas, United States
Redmond, Washington, United States
Port Charlotte, Florida, United States
Kamakura Shi, Kanagawa, Japan
Changchun, Jilin, China
Mauldin, South Carolina, United States
Dorado, , Puerto Rico
Ponce, , Puerto Rico
Białystok, Podlaskie, Poland
Beijing, Beijing, China
Dresden, Sachsen, Germany
Praha 5, , Czechia
Córdoba, , Argentina
Pardubice V, Pardubice, Czechia
Granadero Baigorria, Santa Fe, Argentina
Rosario, Santa Fe, Argentina
Rosario, Santa Fe, Argentina
Xian, Shaanxi, China
Bad Homburg, Hessen, Germany
Ioannina, Ioánnina, Greece
León, Castilla Y León, Spain
Jacksonville, Florida, United States
Piotrkow Trybunalski, łódzkie, Poland
Changde, Hunan, China
Dayton, Ohio, United States
Thessaloniki, Thessaloníki, Greece
Przemysl, Podkarpackie, Poland
Buenos Aires, , Argentina
Rochester, New York, United States
Wenatchee, Washington, United States
Thessaloniki, Thessaloníki, Greece
New Bedford, Massachusetts, United States
Köln, Nordrhein Westfalen, Germany
Dresden, Sachsen, Germany
León, , Spain
Baltimore, Maryland, United States
Warsaw, Mazowieckie, Poland
Tarnów, Małopolskie, Poland
Thessaloniki, , Greece
Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
Lishui City, Zhejiang, China
Prague, , Czechia
A Coruña, A Coruña [La Coruña], Spain
Athens, Attikí (Region), Greece
Shanghai, Shanghai, China
Brandon, Florida, United States
Hodonin, Hodonín, Czechia
Sun City Center, Florida, United States
La Coruña, A Coruña [La Coruña], Spain
Centelles, Barcelona [Barcelona], Spain
Tigard, Oregon, United States
Manassas, Virginia, United States
San Isidro, Buenos Aires, Argentina
Chongqing, Chongqing, China
Brno, Brno Město, Czechia
Brno, Brno Město, Czechia
Ostrava, Moravskoslezský Kraj, Czechia
Ledec Nad Sazavou, Vysočina, Czechia
Praha 4, , Czechia
Leipzig, Sachsen, Germany
Thessaloniki, Thessaloníki, Greece
Ulhasnagar, Maharashtra, India
Matsuyama, Ehime, Japan
Bydgoszcz, Kujawsko Pomorskie, Poland
Barcelona, Barcelona [Barcelona], Spain
Tarnów, , Poland
Prague, , Czechia
A Coruña, , Spain
Athens, , Greece
Brno, , Czechia
Brno, , Czechia
Ostrava, , Czechia
Ledec Nad Sazavou, , Czechia
La Coruña, , Spain
Centelles, , Spain
Duncanville, Texas, United States
Patients applied
Trial Officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported